Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma

November 27, 2017

Join Jill Burke, MSN, NP, and Noopur Raje, MD, from Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to multiple myeloma.

With all of the currently available and emerging treatment options and clinical factors, multiple myeloma management has become multifaceted and complex. Appropriate diagnosis and selection of therapy based on patients and disease characteristics, monitoring response to therapy in addition to adverse effects are all very important to improved patient outcomes. An additional level of complexity in multiple myeloma management lies in devising supportive care treatment plans to manage myeloma or its treatment-associated health conditions. The most common conditions are osteolytic bone lesions and/or osteoporosis that affect 85% of multiple myeloma patients and are the major cause of limitations in their quality of life and performance overall.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Select an optimal management strategy for newly diagnosed multiple myeloma using evidence-based data and patient characteristics.
  • Analyze key clinical considerations in selecting optimal treatment regimen for relapsed/refractory multiple myeloma.
  • Use best practices to manage the adverse events associated with the novel therapies available for multiple myeloma.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas and Medivation, Inc., a Pfizer Company
  • AstraZeneca
  • Celgene Corporation
  • Gilead Sciences, Medical Affairs
  • Lilly
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
  • Taiho Oncology
  • Takeda Oncology

This activity is supported by independent educational grants from:

  • AbbVie
  • Boehringer Ingelheim Pharmaceuticals, Inc.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
09/22/2017
Course expires: 
01/21/2018
Event starts: 
11/27/2017 - 2:00pm
Event ends: 
11/27/2017 - 3:00pm
Cost:
$0.00

Jill Burke, MSN, NP
Dana-Farber/Brigham and Women's Cancer Center |
Massachusetts General Hospital Cancer Center

Noopur Raje, MD
Dana-Farber/Brigham and Women's Cancer Center |
Massachusetts General Hospital Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program. If approved, Activity Code and Approval Number will be posted prior to activity date.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. Universal Activity Number (UAN) will be posted prior to activity date.

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Accreditation Period

Course opens: 
09/22/2017
Course expires: 
01/21/2018

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing